Abstract

Obesity and the metabolic syndrome have hepatic manifestations, including steatosis and progression of fibrosis. In individuals with chronic hepatitis C, obesity is associated with inflammation, insulin resistance, steatosis, progression of fibrosis, and nonresponse to treatment with interferon or peginterferon alpha and ribavirin. Patients with both hepatitis C and obesity-related nonalcoholic fatty liver disease are at greater risk for more advanced liver disease. We review the mechanisms by which obesity may be associated with decreased efficacy of interferon-based therapies in individuals with chronic hepatitis C and the therapeutic strategies that may increase the effectiveness of these therapies in obese individuals.

Keywords

MedicineSteatosisRibavirinNonalcoholic fatty liver diseaseInternal medicineMetabolic syndromeObesityInsulin resistanceGastroenterologyFibrosisFatty liverHepatitis CLiver diseaseDiseaseHepatitis C virusImmunologyVirus

Affiliated Institutions

Related Publications

Nonalcoholic Steatohepatitis

Elizabeth M. Brunt

Nonalcoholic fatty liver disease (NAFLD) is being increasingly recognized as a common liver disorder that represents the hepatic manifestation of the metabolic syndrome, a varia...

2004 Seminars in Liver Disease 477 citations

Publication Info

Year
2006
Type
review
Volume
43
Issue
6
Pages
1177-1186
Citations
137
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

137
OpenAlex

Cite This

Michael Charlton, Paul J. Pockros, Stephen A. Harrison (2006). Impact of obesity on treatment of chronic hepatitis C†. Hepatology , 43 (6) , 1177-1186. https://doi.org/10.1002/hep.21239

Identifiers

DOI
10.1002/hep.21239